GSK gets approval from FDA for Acne treatment

Pharmatimes reported that GlaxoSmithKline‘s acne treatment Fabior foam has been given approval by regulators in the USA.

The US Food and Drug Administration has approved GSK unit Stiefel’s Fabior (tazarotene) foam. It is the only retinoid in a topical foam formulation for the treatment of acne vulgaris in patients 12 years of age and older

Acne is the most common skin problem in the US, affecting about 40 – 50 million Americans at any one time. Therefore this is welcome news for those who suffer with the condition.

Click here to see our latest jobs in the pharmaceutical industry

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in: Industry News, News
CK Logo in place of featured image